Medicines Optimisation & Therapy Review Service

Safe. Evidence-Based. ABPI-Compliant.
Contact UsExplore Training

About the Service

At CliniLink, we deliver clinically-led medicines optimisation services that support NHS primary care in achieving cost-effective, evidence-based prescribing. Our therapy review programmes are developed in partnership with GP practices, PCNs, and ICBs, and are aligned with local formularies and national guidelines.

Services are available via direct NHS commissioning or can be supported through unrestricted educational grants from the pharmaceutical industry, fully aligned with the ABPI Code of Practice. All reviews are conducted within NHS systems using DSP Toolkit-compliant platforms, with no patient-identifiable data extracted. Our team operates under robust governance, GDPR compliance, and NHS-approved data-sharing agreements.

Each programme is designed to improve prescribing quality, reduce clinical risk, and deliver lasting improvements in care, supported by training to embed change sustainably within local pharmacy teams.

Our Strategy

  • Secure remote access via DSP Toolkit-compliant platforms integrated with EMIS Web or SystmOne

  • In-house clinical pharmacists and prescribers with full employment checks and indemnity cover

  • Fully ABPI, GDPR, and IG-compliant operations

  • Structured outcome reporting with measurable clinical and financial impact

  • Linked training and mentoring to support workforce development and sustainability

Therapeutic Review Areas

We support therapy reviews across a range of high-priority clinical areas, including but not limited to:

  • Cardiovascular reviews – including atrial fibrillation, lipid management, and hypertension

  • Diabetes care – including appropriate prescribing of blood glucose testing strips and pen needles

  • Women’s health

  • Respiratory care

  • Dry eye disease

  • Pain management

  • Continence prescribing

  • Bone health

  • Fraility Reviews
  • Dermatology Reviews

  • Oral Nutritional Supplements

Our therapy review services aim to improve prescribing safety and efficiency, increase patient access to appropriate treatment, reduce unwarranted variation, and deliver measurable cost savings—while empowering local GP and pharmacy teams through clinical training and mentoring. All services are delivered in full alignment with NHS governance standards and the ABPI Code of Practice.

Amiloride vs Spironolactone in Resistant Hypertension: A Promising Alternative or Just Non-Inferior?

Resistant hypertension remains a persistent challenge in primary care and specialist settings alike. Despite guideline-directed therapy with ACE inhibitors or ARBs, calcium channel blockers, and thiazide-like diuretics, many patients continue to have suboptimal blood...

QR4: A Smarter Way to Predict Cardiovascular Risk

Cardiovascular disease (CVD) continues to be the leading cause of death in the UK and globally, despite decades of public health advances and improvements in treatment. As clinicians, our ability to accurately assess risk is central to preventing serious...

NICE AI Skin Cancer Guidance: What GPs Need to Know About New Referral Tools

The integration of artificial intelligence (AI) into primary care is no longer a futuristic concept—it’s here. With the recent NICE early value assessment (HTE24) guidance focusing on AI for assessing and triaging suspicious skin lesions, GPs are now at the forefront...

National Heart Week: Five Simple Lifestyle Tips for a Healthier Heart

National Heart Week (April 29 – May 5) is a perfect time for healthcare professionals to encourage simple lifestyle changes that make a big impact on heart health. Whether you’re a GP, nurse, pharmacist, or allied health professional, your brief advice can empower...

NICE Approval: A New Option for Endometriosis

Ryeqo for Endometriosis: A New Treatment, A Renewed Responsibility With NICE's recent approval of Ryeqo (relugolix, estradiol, norethisterone acetate) for use on the NHS, women of reproductive age now have a new treatment option for endometriosis. But this advancement...

BMS Update: How to Safely Use HRT with Incretins

In April 2025, the British Menopause Society (BMS) published new clinical guidance to support healthcare professionals managing women who are prescribed both incretin-based therapies and hormone replacement therapy (HRT). This comes at a crucial time, as GLP-1...

Asthma Reimagined: Understanding the 2024 NICE Guidelines for Primary Care

The 2024 NICE asthma guideline update marks a transformative step in asthma care, especially within primary care settings. With an emphasis on objective diagnosis, safer prescribing, and sustainability, this new guidance aims to improve outcomes and reduce variation...

Primary Care Pharmacist Jobs in the UK: Busting Myths, Exploring Opportunities, and Taking the Next Step

The landscape of primary care in the UK is evolving, presenting numerous opportunities for pharmacists to play a pivotal role. However, misconceptions and uncertainties often deter many from exploring these roles. At CliniLink, we've engaged with pharmacists across...

Melatonin for Perimenopause and Menopause: Does It Improve Sleep Quality?

Melatonin for Perimenopause and Menopause: Does It Improve Sleep Quality? Many women experience disrupted sleep during perimenopause and menopause, often due to hormonal changes that affect the body's natural circadian rhythm. As melatonin—the sleep hormone—declines...

Understanding the Changing Economics of NHS Drug Pricing: An Essential Guide for UK Clinical Pharmacists

Recent headlines reveal growing concerns among major pharmaceutical companies regarding the NHS rebate system. Companies such as AstraZeneca, GSK, and Pfizer have warned that high repayment rates,reported to reach up to 22.9% for newer medicines, are placing...